Navigation Links
Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
Date:12/12/2007

VIENNA, Austria, December 12 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has established a Scientific Advisory Board and has appointed three outstanding scientists to form the nucleus of this advisory body. Members of f-star's Scientific Advisory Board include:

Professor Sir Ravinder Maini, Imperial College, London, UK

Sir Ravinder Maini is Emeritus Professor of Rheumatology at Imperial College, University of London, UK, and currently a member of the Trust Board of The Kennedy Institute of Rheumatology, London. He is a pioneer in the research and development of anti-TNF therapy, played a vital role in research and clinical development of infliximab (Remicade), and was a non-Executive Director of Domantis, the antibody engineering company founded in 2000 and acquired by GSK in 2006.

Professor Anthony Rees, MIP Technologies AB, Lund, Sweden

Anthony Rees is CEO of MIP Technologies AB, a company developing molecularly imprinted polymers. He was previously Scientific Director at the French biotech company Synt:em and before that Head of the School of Biology and Biochemistry at the University of Bath, UK. In 1989, Dr Rees was scientific co-founder of Oxford Molecular plc which marketed antibody modelling software developed by his group at Universities of Oxford and Bath, now available as a web-based modelling service and widely used in antibody engineering.

Professor Sir Gregory Winter, MRC Laboratory of Molecular Biology, Cambridge, UK

Sir Gregory Winter is Deputy Director of the Medical Research Council's Laboratory of Molecular Biology and Head of the Division of Protein and Nucleic Acids Chemistry. Sir Gregory developed technologies for making human antibodies, and most of the therapeutic antibodies on the market were developed using methods devised by him. He was a founder and Director of Cambridge Antibody Technology, now part of MedImmune, AstraZeneca's biologics business unit. In 2000 he co-founded Domantis, recently acquired by GSK, and acted as Director and Chairman of the Scientific Advisory Board.

"We are enthusiastic and feel highly privileged that these pioneers in antibody engineering and development will support us in our mission to develop next generation therapeutics based on our Modular Antibody Technology", said Gottfried Himmler, Chief Executive Officer, f-star. "Their in-depth experience and advice will be an invaluable asset in our efforts to build f-star into a major player in the next generation antibody field."

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Modular Antibody Technology allows for the creation of antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb squared).

The Company was founded by a team of highly experienced antibody engineering and biotech executives. Seed-financed by Austrian government agencies and Atlas Venture in 2006, the Company raised EUR 9.0m in a Series A financing round from Aescap Venture, Atlas Venture and Novo A/S in 2007. In total, the Company has raised more than EUR 13m so far.
For more information, visit http://www.f-star.com

Company contact:

Dr. Eugen Stermetz

CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-72055-4215

Gastgebgasse 5-13

A-1230 Vienna, Austria

http://www.f-star.com

office@f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78-44-940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
2. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
3. Antibody Helps Repair MS Nerve Damage
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
6. Antibody responses in patients with Lyme arthritis
7. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
8. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
9. MSU engineering team designs innovative medical device
10. Specialty Blades, Inc. Expands Management Team With New VP Engineering
11. McGraw-Hill Professional Enhances Library Access to Medical and Engineering Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... Beverly Hills, CA (PRWEB) , ... December 02, ... ... and reconstructive surgeon in Beverly Hills, California, will be included in the 2016 ... is given to exceptional professionals based on the amalgamation of their education, experience, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline clinicians ... of pain management. , The demand for supplemental training related to pain ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016  PipelineRx, a leading medication management technology ... demonstrations of its SaaS-based telepharmacy platform, PowerGridRx™ ... 2016 Midyear Clinical Meeting and Exhibition, December 5-7 ... nearly 300 hospital clients nationally, the Company is ... to dramatically improve pharmacy operations, enhance patient safety, ...
(Date:12/2/2016)... Texas , Dec. 2, 2016  Maxor National Pharmacy ... acquisition of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s ... physicians, manufacturers, and payers an industry-leading specialty pharmacy. ... , ...
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
Breaking Medicine Technology: